Abstract. To investigate the pathophysiological role of phospholipase D (PLD)-mediated signaling, changes in the expression of the PLD isozymes PLD1 and PLD2 were investigated in the rat kainic acid (KA) model of human temporal lobe epilepsy. Western blot analysis showed a significant increase in the expression of PLD1 and PLD2 in the postictal hippocampus. PLD1 immunoreactivity increased preferentially in the CA3 and CA1 regions, where pyramidal neurons are susceptible to temporal lobe epilepsy. Experiments employing double immunofluorescence revealed that the cells expressing PLD1 were GFAPexpressing reactive astrocytes. By contrast, PLD2 immunoreactivity increased strikingly in infrapyramidal, but not in suprapyramidal granule cells of the postictal dentate gyrus, fitting well with results of the PLD activity assay. Considering that PLD belongs to a key signaling pathway, this result suggests that changes in granule cell activity in the dentate gyrus after seizures occurs specifically between the supra-and infrapyramidal blades. In addition, enhanced immunoreactivity of PLD2 was observed in the reactive astrocytes of the CA1, CA3, and hilar subregions, but its temporal pattern is different from that of PLD1. Taken together, our results suggest that PLD1 and PLD2 exercise their unique pathophysiological functions in the rat hippocampus after KA-induced seizures.
INTRODUCTION
Phospholipase D (PLD) catalyzes the hydrolysis of the major membrane phospholipid, phosphatidylcholine, to generate phosphatidic acid (PA), and choline and is assumed to play an important function in cellular regulation (1, 2) . To date, 2 distinct isoforms of mammalian PLD have been cloned, specifically, PLD1 and PLD2. These isoforms share about 50% amino acid homology, but exhibit quite different regulatory properties (3) (4) (5) . Both proteins appear to be complexly regulated, usually in an agonist-and cell-specific manner, and the molecular mechanisms underlying their functions have not been fully elucidated. Furthermore, although many studies focusing on the regulation of PLD have been reported, the physiological roles of these isozymes have yet to be defined.
The identification of PLD activation as a novel signal transduction pathway has created particular interest in the function of PLD in the nervous system. Recent investigations have showed that PLD1 and PLD2 are expressed in the mammalian brain (6) (7) (8) (9) . Although our previous investigation revealed spatio-temporal alterations in the activity and expression of PLD1 in the hippocampus after brain insults (10) , little is known about the pathophysiological role of PLD-mediated signaling in disease models of the brain.
As a potent agonist for the ␣-amino-3-hydroxy-5-methylisoxazole-4-propionic acid/kainate class of glutamate receptor, kainic acid (KA) is an excitotoxic agent (11) . Experimentally, KA induces neuronal death with astrocytic and microglial reactions (12) (13) (14) , which is, at least in part, a consequence of excessive generation of reactive oxygen species (15) (16) (17) . Several recent studies have shown that reactive oxygen species stimulate PLD activity in several kinds of cells (18) (19) (20) . This, therefore, raises the possibility that PLD can be upregulated in the brain following seizure insults.
In the present study, using immunohistochemistry and Western blot analysis, we investigated whether the expression of PLD1 and PLD2 in the hippocampus is altered after a KA-induced seizure. Our results demonstrate for the first time that expression of PLD subtypes is differentially induced in the hippocampus following seizure in the animal model of temporal lobe epilepsy.
MATERIALS AND METHODS

Experimental Animals and Tissue Processing
Male Sprague-Dawley rats (250-300 g) received a single intraperitoneal injection of KA (10 mg/kg) dissolved in sterile saline. Their behavior was then observed constantly for the next 6 hours (h). Only animals with stage 5 seizures (i.e. the rearing and falling stage, as described by Zhang et al [21] ) were used for this study. Control animals were injected with sterile saline. Animals were maintained for 12 h, 1, 2, 3, 5, and 10 days (d) after KA injection. Seven animals were taken for each time point; 3 rats were used for Western blot analysis, 3 rats for PLD Using the New Zealand white rabbit, antisera were raised against the N-terminal peptide of PLD1 and PLD2 corresponding to amino acid residues 1-12 of rat PLD1 (MSLRSEARVNTS) and amino acid residues 1-19 of human PLD2 sequence (MTATPESLFPTGDELDSSQ), respectively, as previously described (22) . For affinity purification of the antibody, the peptide was coupled to Affi-Gel 15 (Bio-Rad, Hercules, CA) following the manufacturer's instructions with slight modification. Five ml of antiserum was incubated with peptide-conjugated Affi-Gel 15 (5 mg of peptide in 1 ml of Affi-Gel 15) overnight at 4ЊC. The column was then washed with 20 ml HEPES/ NaOH, pH 7.0, 200 mM NaCl, 0.1 % Triton X-100, and the antibody was eluted with a buffer (0.1 M glycine/HCl, pH 2.5) into tubes containing 1 M Tris-HCl, pH 8.0 for neutralization.
Generation of Mouse Monoclonal Antibody
Specific for PLD2
The fragment of PLD2 (724-825 amino acids) was fused to GST. The production of a monoclonal antibody specific to PLD2 was completed as detailed previously (23) . Briefly, female BALB/c mice (7 to 8 weeks old) were immunized with the purified GST-fusion protein several times. The spleen cells from the immunized mice were fused with SP 2 myeloma cells. Standard fusion, screening, and cloning procedures were followed. Culture supernatants were screened for immunoblot analysis. The cells from the positive wells were cloned twice to ensure monoclonality.
Western Blot Analysis
For immunoprecipitation, hippocampi were dissected at 12 h, 1, 3, 5, and 10 d after KA injection and homogenized in radio immunoprecipitation assay buffer (20 mM HEPES, pH 7.2, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 150 mM NaCl, 10 g/ml leupeptin, 10 g/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride). After incubation for 30 min in an ice bath, the homogenates were centrifuged and then the lysate supernatant was precleared by incubation with preimmune IgG and protein A sepharose for 30 min. Precleared cell lysates were incubated with anti-PLD antibody, and 30 l of 50% slurry of protein A sepharose for 4 h. The immune complex was collected by centrifugation and washed 5 times with ice-cold buffer containing 20 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 2 mM Na 3 VO 4 , 10% glycerol, 1% Nonidet P-40, followed by addition of SDS sample buffer, and boiling. For Western blot analysis, the recovered protein was resolved on a sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel and blotted to PVDF membrane. The blot was probed with anti-PLD antibody. Immunoreactive bands were visualized by chemiluminescence using horseradish peroxidaseconjugated anti-rabbit IgG and enhanced chemiluminescence (ECL; Amersham, Arlington Heights, IL).
PLD Activity Assay
For PLD activity assay, coronal slices (100-m-thick) at the levels of septal hippocampus were cut with McIlwain tissue chopper. The infrapyramidal or suprapyramidal regions of hippocampus were selectively cut out from the slices under microscopic observation and homogenized in buffer consisting of 20 mM Hepes, pH 7.2, 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 0.5 mM PMSF, and 10 g/ml leupeptin. Each homogenate was centrifuged at 500 g for 5 min and the pellet was discarded. The supernatant was centrifuged at 10,000 g for 1 h and the pellet was resuspended in homogenization buffer and designated as membrane fraction. PLD activity was measured by the formation of 
Immunohistochemistry and Double Immunofluorescence Histochemistry
Free-floating sections (25-m-thick) at the levels of septal hippocampus were selected and processed for PLD1 or PLD2 immunohistochemistry. The sections were incubated overnight at 4ЊC with a rabbit polyclonal antibody specific for PLD1 or PLD2, or a mouse monoclonal antibody to PLD2. Primary antibody binding was visualized using a peroxidase-labeled goat anti-rabbit antibody or peroxidase-labeled goat anti-mouse antibody (Jackson ImmunoResearch, West Grove, PA; diluted at 1:200) and 0.05% 3,3Ј-diaminobenzidine tetrahydrochloride and 0.01% H 2 O 2 as substrate. The specificity of PLD1 or PLD2 immunoreactivity was described in a recent report (22) and was confirmed by the absence of immunohistochemical staining in sections from which the primary antibody was omitted, or in which it was substituted with nonspecific rabbit IgG. For double immunofluorescence histochemistry, sections were incubated overnight with a combination of a rabbit polyclonal antibody to PLD1 or PLD2 and either a mouse monoclonal antibody to GFAP (Chemicon International, Inc., Temecula, CA; diluted 1: 400) or a mouse monoclonal antibody to neuronal nuclear antigen (NeuN, Chemicon; diluted at 1:100) at 4ЊC. The sections were then incubated for 2 h at room temperature with a mixture of FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch; diluted at 1:50) and Cy3-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch; diluted at 1:500). Control sections were prepared as described above. Slides were viewed using a confocal microscope (MRC-1024, Bio-Rad). Images were converted to TIFF format, and contrast levels of images were adjusted using Adobe Photoshop version 6.0 (Adobe Systems, Inc., San Jose, CA). 
RESULTS
Western Blot Analysis
Immunoblotting with an antibody to PLD1or PLD2 showed a single labeled band (120 kDa and 105 kDa, respectively) in protein extracts from the hippocampus of control and experimental rats (Fig. 1) . PLD1 protein was barely detectable in the hippocampus of control rats, but increased slightly during the first 12 h after KA injection, and was markedly upregulated thereafter, with maximal levels observed at 5 d. These levels subsequently declined by 10 d, the latest time point examined (Fig. 1A) . The temporal pattern for PLD2 immunoreactivity was similar to that of PLD1. PLD2 protein levels were very low in the hippocampus of the control rats. PLD2 expression gradually increased in the hippocampus after KA injection, peaking after 3 d and decreasing thereafter (Fig. 1B) .
Temporal Profiles of PLD1 Immunoreactivity following KA-Induced Seizures
The distribution and cellular localization of PLD1 protein in the hippocampus following KA injection were examined using immunohistochemistry. As in a previous study (6), immunohistochemistry demonstrated a low level of basal PLD1 immunoreactivity in the hippocampus ( Fig. 2A-C) . Within 12 h after KA injection, labeled profiles had appeared adjacent to the pyramidal cell layer, most conspicuously in the CA3 region (Fig. 2D) . By 1 d after KA injection, increased immunoreactivity over the CA3 region was more evident when compared with controls, and extended into the dentate hilar region and also into the molecular layer of the dentate gyrus (Fig. 2E, F) . As in the immunoblot analysis, the most prominent intensity in immunohistochemical staining occurred between 3 d and 5 d after KA injection. At 3 d, PLD1 immunoreactivity was distributed fairly homogeneously over the CA1 and CA3 regions of the hippocampus and the dentate gyrus (Fig. 2G, I ) and this expression pattern was maintained for 10 d following KA injection (Fig. 2H,  J) . Inspection of immunolabeled sections under higher magnification revealed that PLD1 immunoreactivity was localized to cells displaying the morphology of reactive astrocytes (Fig. 2F, I , J).
Temporal Profiles of PLD2 Immunoreactivity Following KA-Induced Seizures
The spatio-temporal pattern of PLD2 immunoreactivity following KA injection was distinct from that of PLD1. Both polyclonal and monoclonal antibodies specific to PLD2 showed similar immunohistochemical profiles (data not shown). Very weak immunoreactivity for PLD2 could be seen in neurons of the granule cell and pyramidal cell layers in saline-injected rats at any time point (Fig. 3A-C) . The dentate granule cells are arranged in a densely packed layer with 2 sections called the suprapyramidal blade (i.e. the portion adjacent to CA1 area) and the infrapyramidal blade. Within 12 h of KA injection, increased immunoreactivity was clearly evident in granule cells in the infrapyramidal blade, but comparable increases were not observed in the suprapyramidal granule cells (Fig. 3D, F) . At 1 d after KA injection, further increased PLD2 immunoreactivity in the infrapyramidal granule cells was evident when compared with controls. In addition, PLD2 immunoreactivity had increased preferentially in the pyramidal cell layer of the CA3 and also in the dentate hilar region (Fig. 3E, G, H) . This expression pattern was correlated with the activity of ARF-dependent PLD (Fig. 4) .
At 3 d after KA injection, increased immunoreactivity was still observed in the infrapyramidal granule cells and extended into the pyramidal cells of the CA fields of the hippocampus (Fig. 5A-D) . In addition, more weakly labeled profiles had appeared adjacent to the pyramidal cell layer and within the dentate hilar region. The latter signals had increased preferentially in the CA1 and CA3 regions and the dentate hilar region by 5 d (data not shown). At 10 d after KA injection, PLD2 immunoreactivity was still abundant in the CA1 sector, but PLD2 immunoreactivity in the infrapyramidal granule cells and pyramidal cells returned toward baseline levels (Fig. 5E, F) .
Cellular Localization of PLD1 and PLD2 Immunoreactivity
Double immunofluorescence histochemistry revealed that PLD1 immunoreactive cells in the CA1 region following KA-induced seizures were also immunoreactive for GFAP (Fig. 6A-C At 12 h after KA injection, PLD1 immunoreactivity appeared to be slightly increased in the CA3 region. E: At 1 d, increased immunoreactivity in the CA3 region became more evident, and weakly labeled profiles appear in the dentate hilar region and also in the molecular layer of the dentate gyrus. F: Higher magnification of the boxed area in (E). G, H: PLD1 immunoreactivity was further increased along the CA sectors and in the dentate hilar region at 3 d (G) and remained intense at 10 d (H). I, J: Higher magnifications of the CA1 sector from (G) and (H), respectively. Abbreviations: DG, dentate gyrus; pcl, pyramidal cell layer; sr, stratum radiatum. Scale bars: A, D, E, G, H ϭ 300 m; B, C, F, I, J ϭ 100 m.
double-labeled cells in the infrapyramidal blade relative to the suprapyramidal blade (Fig. 6D-F) . This finding was very consistently observed in all animals studied. PLD2 immunoreactivity was also observed in cells in the CA1 region and the dentate hilar region, which were identified as GFAP-labeled astrocytes by double immunofluorescence for PLD2 and GFAP (Fig. 6G-L) .
DISCUSSION
The major finding in the present study is the increased protein expression of both PLD1 and PLD2 in the brain of an animal model for human temporal lobe epilepsy. PLD1 was previously shown to be activated and upregulated in the rat hippocampus following ischemic brain insults (10) . However, it is still unknown whether expression of PLD2 is altered in disease models of the brain. In this study, we characterized for the first time the expression pattern and cellular localization of PLD1 and PLD2 in the rat hippocampus after KA-induced seizures.
The present results demonstrate that astrocytes reactive to excitotoxic injury upregulate PLD1 protein. PLD1 is expressed at very low levels in control rats, implying that D) and (E). Abbreviations: so, the stratum oriens; DG, dentate gyrus; GL, granule cell layer; pcl, pyramidal cell layer; PL, dentate hilar region; sr, stratum radiatum. Scale bars: A, D, E ϭ 300 m; B, C, F-H ϭ 100 m.
PLD1 is not important in normal glial cell functions. However, PLD1 immunoreactivity following KA injection was preferentially increased in the CA3 and CA1 subregions, where pyramidal neurons are susceptible to KA-induced seizures (11, 24, 25) . Moreover, double immunofluorescent staining showed that all cells demonstrating PLD1 immunoreactivity also exhibited GFAP immunoreactivity. Although the putative role of PLD1 in the pathophysiological processes following seizures remains to be determined, it is possible that the induction of PLD1 in reactive astrocytes is related to repair and regeneration processes, rather than to destructive processes. This possibility is supported by our results from immunohistochemistry and Western blot analysis, which showed that PLD1 expression peaks around 5 d after seizure insults and is maintained at 10 d, when repair and remodeling occur (26) . In parallel with these results, we previously demonstrated that PLD1 expression in reactive astrocytes in the rat hippocampus peaks at 7 d to 14 d after ischemic insults and is maintained at 14 d (10). Taken together, our present findings suggest that PLD1 is upregulated in reactive astrocytes in response to brain insults at the late stage when remodeling occurs.
In the present study we demonstrated for the first time that PLD2 expression is changed in the brain of animal models of nervous diseases. Interestingly, our results show that the expression pattern of PLD2 differs strikingly between the supra-and infrapyramidal blades of the dentate gyrus after seizures, fitting well with results of the PLD activity assay. Several reasons suggest that asymmetrical expression of PLD2 in the dentate gyrus after seizures is not an artifact. First, the expression of PLD2 in the dentate gyrus began to increase at 12 h, peaked at 1 d to 3 d, and returned to the basal level at expression in adjacent sections and double immunofluorescence histochemistry indicates that cells colocalizing PLD2 with NeuN, a neuronal marker, were observed mainly in the infrapyramidal blade compared to the suprapyramidal blade.
In support of our results, a recent study using extracellular recordings showed that excitability in brain slices of epileptic rats is profoundly larger in the infrapyramidal blade than in the suprapyramidal blade of the dentate gyrus, suggesting that the infrapyramidal blade may play a greater role in activating the hippocampus (27) . In addition, 2 lines of investigation suggest that inhibitory circuitry including ␥-aminobutyric acid-immunoreactive neurons is denser in the suprapyramidal blade than in the infrapyramidal blade (28, 29) . Considering the fact that PLD is one of the key enzymes in the lipid metabolism which produces several second messengers, our results
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J Neuropathol Exp Neurol, Vol 63, August, 2004 suggest that changes in granule cell activity in the dentate gyrus after seizures is not homogeneous, but occurs specifically between the supra-and infrapyramidal blades.
What is the significance of the differential expression of PLD2 in neurons in the dentate gyrus after KA-induced seizures? It is well known that mossy fiber axons in the dentate gyrus undergo sprouting and remodeling of their terminal field in a variety of experimental models of epilepsy and in the human epileptic temporal lobe (30) (31) (32) . Interestingly, Sutula et al observed that the sprouted axon collaterals from granule cells in the infrapyramidal blade crossed the hilus and projected into the supragranular layer of suprapyramidal blade, but not vice versa, after KA-induced seizures (33) . The projection patterns of biocytin-filled sprouted mossy fiber axons observed in anatomic studies is consistent with the anatomic feature of the responses and the pattern of interblade projection from infrapyramidal to suprapyramidal blade in electrophysiological studies (34) . In addition, a recent in vitro study provided evidence that PLD2 functions as a signaling molecule to mediate the neurite outgrowth of cerebellar granule neurons (35) . These findings together with our observations lead us to speculate that PLD2 expressed differentially in the infrapyramidal blade of the dentate gyrus may play a role in the characterization of the spatial distribution of the sprouted mossy fiber pathways after epileptic seizures. It is of interest to investigate this point in the future.
We also observed temporally defined increases in PLD2 immunoreactivity in the pyramidal cell layer of the CA1, CA3, and hilar subregions. Double immunofluorescent staining demonstrated that only a proportion of PLD2-immunoreactive cells in these subregions exhibited GFAP-immunoreactivity. Whereas neuronal PLD2 immunoreactivity peaked at 1 d to 3 d and returned toward baseline levels 10 d after seizure insult, the expression of PLD2 in reactive astrocytes at sites of intense neuronal damage, including the CA1 and CA3 area, was maintained at 10 d after KA injection. The sustained upregulation of PLD2 in reactive astrocytes suggests that PLD2 may also be involved in the regulation of astroglial reactions to seizure insults. However, considering that the increase in PLD2 immunoreactivity of reactive astrocytes appeared to have a delayed onset and was significantly weaker than that of PLD1, it is likely that PLD1 and PLD2 differentially mediate the astroglial reaction in the rat hippocampus after KA-induced seizures.
In summary, our results demonstrate in the rat KA model of human temporal lobe epilepsy that 1) PLD1 is upregulated in reactive astrocytes at the repair and remodeling stage after seizure; 2) PLD2 is prominently increased in granule cells in the dentate gyrus, especially in the infrapyramidal blade; 3) and PLD2 is also increased in reactive astrocytes and pyramidal cells in the hippocampus. Thus, PLD1 and PLD2 may have their unique pathophysiological functions in the hippocampus after brain insults. Further investigations using in vivo systems in which the activity of PLD isozymes is specifically altered will give more information about the functional significance of PLD isozymes under pathophysiological conditions.
